DoD Prostate Cancer Research Program Funding Opportunities: June Deadline

How to Apply: 

The FY22 Defense Appropriations Act is anticipated to provide funding for the PCRP to support innovative, high-impact prostate cancer research.  The managing agent for the anticipated program announcements/funding opportunities is the CDMRP at the U.S. Army Medical Research and Development Command (USAMRDC).

The FY22 PCRP funding opportunity announcements for the following award mechanisms are posted on the website.

The mission of the FY22 PCRP is to fund research that will lead to the elimination of death from prostate cancer and enhance the well-being of Service Members, Veterans, and all the men and their families who are experiencing the impact of the disease.  Within this context, the PCRP is interested in supporting research that addresses specific gaps in prostate cancer research and clinical care; therefore, applications are required to address one or more of the following FY22 PCRP Overarching Challenges:

  • ·        Improve quality of life to enhance outcomes and overall health and wellness for those impacted by prostate cancer

Applications should aim to understand the impact of prostate cancer on quality of life for the cancer survivor, their family, caregivers, and their community with the goal of improving and enhancing quality of life and overall health and wellness.  Studies should consider both short- and long-term quality of life outcomes.  Areas of particular interest include:

o   The mental and emotional health of patients and their families/caregivers

o   Impact of quality of life considerations on decision-making after diagnosis and/or treatment

o   Identification of vulnerable groups of men and their families at great risk of quality of life detriments

o   Translation of factors or interventions that improve quality of life outcomes and overall health and wellness

  • ·        Develop treatments that improve outcomes for men with lethal prostate cancer

Applications must be directly related to prostate cancer with a high risk of death, including high-risk, very high-risk, and metastatic prostate cancer.  Applications should not focus on active surveillance, low-risk and intermediate-risk prostate cancer, and/or biochemical recurrence.  Refer to the National Comprehensive Cancer Network guidelines for risk assessment definitions (

  • ·        Advance health equity and reduce disparities in prostate cancer

Applications must be directly relevant to the better understanding and/or reduction of inequities and disparities that impact a person, their family, or their caregiver's ability to prevent, detect, manage, and survive prostate cancer. 

Inequities may arise from socioeconomic status, race or ethnicity, geography, environment, lifestyle, sexual and/or gender identification, access to care (in rural or urban settings), or other factors.

Health inequities may include physical, mental, or emotional health differences, as well as social and financial differences experienced primarily in high-risk or underserved prostate cancer patients. 

High-risk populations include, but are not limited to, people of African descent (including Caribbean), genetically predisposed populations, Service Members, and Veterans.

Underserved populations include, but are not limited to, men with limited access to clinical care and resources (in rural or urban settings), and sexual and/or gender minorities.

  • ·        Define the biology of prostate cancer progression to lethal prostate cancer to reduce death

Applications must be directly related to high-risk, very high-risk, and metastatic prostate cancer.  Refer to the National Comprehensive Cancer Network guidelines for risk assessment definitions (


Funding Opportunities-FY22 PCRP, Congressionally Directed Medical Research Programs (CDMRP), US DoD (


Exploration – Hypothesis Development Award NEW for FY22 –Letter of Intent Dye June 2, 2022

Investigators at or above the level of postdoctoral fellow (or equivalent)

  • ·     Supports the exploration of highly innovative, untested, potentially high-gain concepts, theories, paradigms, and/or methods that address an important problem relevant to one or more FY22 PCRP Overarching Challenges.
  • ·     Provides investigators the opportunity to pursue serendipitous observations that may reveal entirely new avenues for investigation.
  • ·     Presentation of preliminary data is strongly discouraged.
  • ·     Reviewers will be blinded to the identity of the Principal Investigator (PI), collaborators, and their organization(s).
  • ·     Clinical research and clinical trials are not allowed.
  • ·     Must address at least one of the FY22 PCRP Overarching Challenges.
  • ·     The maximum allowable funding for the entire period of performance is $100,000 for direct costs.
  • ·     Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.
  • The maximum period of performance is 2 years.

For more information, please contact Jill Sherman, International Research Facilitator at

External Deadline: 
Thursday, June 2, 2022
Funding Source: 
Funding Level: